603970.SHG Sino-Argi Leading Biosciences
- Market cap
- CNY 2.70B
- P/E
- 17.9x
- P/B
- 1.65x
- ROE
- 10.8%
- Dividend yield
- 5.31%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603970.SHG undervalued?
Graham number603970.SHG trades 14.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sino-Argi Leading Biosciences fundamental analysis
No fundamental analysis for Sino-Argi Leading Biosciences yet.
Sino-Argi Leading Biosciences stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sino-Argi Leading Biosciences
Sino-Agri Leading Biosciences Co.,Ltd engages in pesticide distribution in China and internationally. The company sells technical materials, formulations, and related products. It also provides plant protection products, application demonstrations, processing, and packaging. In addition, the company offers insecticides, fungicides, and herbicides products. The company was founded in 2009 and is headquartered in Beijing, China. Sino-Agri Leading Biosciences Co.,Ltd is a subsi…
Full company profileSino-Argi Leading Biosciences financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sino-Argi Leading Biosciences annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.40B | 3.50B | 3.73B | 4.34B | 6.64B | 8.82B | 11.7B | 10.5B | 10.6B | 11.2B | 11.8B |
| Gross Profit | 400M | 409M | 410M | 441M | 516M | 530M | 727M | 702M | 718M | 740M | 666M |
| Operating Income | 75.4M | 123M | 157M | 148M | 211M | 239M | 325M | 315M | 301M | 348M | 340M |
| EBITDA | 201M | 180M | 195M | 217M | 262M | 290M | 365M | 342M | 345M | 283M | 248M |
| Net Income | 81.7M | 90.3M | 115M | 119M | 132M | 170M | 210M | 225M | 203M | 173M | 172M |
| EPS | 0.41 | 0.44 | 0.43 | 0.44 | 0.49 | 0.63 | 0.78 | 0.84 | 0.76 | 0.64 | 0.64 |
| Balance Sheet | |||||||||||
| Total Assets | 2.58B | 2.78B | 2.58B | 2.74B | 4.02B | 4.74B | 6.24B | 6.01B | 5.60B | 4.91B | 5.88B |
| Total Liabilities | 2.15B | 1.92B | 1.63B | 1.69B | 2.88B | 3.46B | 4.76B | 4.41B | 3.92B | 3.18B | 4.13B |
| Shareholders' Equity | 345M | 783M | 865M | 956M | 1.03B | 1.17B | 1.32B | 1.44B | 1.52B | 1.58B | 1.60B |
| Cash & Short-term Investments | 260M | 406M | 332M | 475M | 1.51B | 1.47B | 2.93B | 1.66B | 1.41B | 250M | 240M |
| Total Debt | 1.21B | 782M | 753M | 753M | 1.12B | 957M | 910M | 649M | 633M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 152M | 519M | 65.7M | 219M | 352M | 325M | 1.54B | -920M | 307M | -78.3M | - |
| Capital Expenditure | 36.8M | 55.4M | 8.99M | 2.67M | 15.0M | 3.99M | 3.44M | 4.37M | 2.18M | 1.37M | 4.43M |
| Free Cash Flow | 115M | 463M | 56.7M | 216M | 337M | 321M | 1.53B | -924M | 305M | -79.7M | 187M |
| Ratios | |||||||||||
| ROE | 23.7% | 11.5% | 13.3% | 12.4% | 12.9% | 14.5% | 16.0% | 15.6% | 13.4% | 10.9% | 10.8% |
| ROA | 3.2% | 3.2% | 4.5% | 4.3% | 3.3% | 3.6% | 3.4% | 3.7% | 3.6% | 3.5% | 2.9% |
| Net Profit Margin | 2.4% | 2.6% | 3.1% | 2.7% | 2.0% | 1.9% | 1.8% | 2.1% | 1.9% | 1.5% | 1.5% |
| Debt to Equity | 3.51x | 1.00x | 0.87x | 0.79x | 1.10x | 0.82x | 0.69x | 0.45x | 0.42x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sino-Argi Leading Biosciences dividends
- Dividend yield
- 5.31%
- Forward dividend
- 0.32 CNY
- Payout ratio
- 82.9%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 143M | 0.53 | 82.9% |
| 2024 | CNY 145M | 0.54 | 71.3% |
| 2023 | CNY 123M | 0.46 | 54.9% |
| 2022 | CNY 67.2M | 0.25 | 32.0% |
| 2021 | CNY 57.6M | 0.21 | 33.8% |
| 2020 | CNY 48.0M | 0.18 | 36.2% |
| 2019 | CNY 40.0M | 0.15 | 33.7% |
| 2018 | CNY 71.5M | 0.27 | 61.9% |
| 2017 | CNY 95.2M | 0.46 | 105.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 13, 2023.
Who owns Sino-Argi Leading Biosciences
- Insiders 64.87%
- Institutions 1.66%
- Public & others 33.47%
- Shares outstanding 269M
- Free float 102M
Sino-Argi Leading Biosciences company profile
- Company name
- Sino-Argi Leading Biosciences
- Ticker
- 603970.SHG
- ISIN
- CNE100002TN4
- Exchange
- Shanghai Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 736
- Fiscal year end
- December
- Address
- Global Finance & News Center, Beijing, China, 100052
- Phone
- 86 10 5933 7477
- Website
- sino-agri-sal.com
About Sino-Argi Leading Biosciences
Sino-Agri Leading Biosciences Co.,Ltd engages in pesticide distribution in China and internationally. The company sells technical materials, formulations, and related products. It also provides plant protection products, application demonstrations, processing, and packaging. In addition, the company offers insecticides, fungicides, and herbicides products. The company was founded in 2009 and is headquartered in Beijing, China. Sino-Agri Leading Biosciences Co.,Ltd is a subsidiary of China National Agricultural Means of Production Group Corporation.
Sino-Argi Leading Biosciences management
5- Mr. Baishu HuangGM, Secretary & Director · born 1979
- Ms. Chanmi LeeAccounting Supervisor, Financial Director & Director · born 1984
- Mr. Kai KangDeputy GM, Operations Manager & Director · born 1976
- Mr. Mingguang LiExecutive VP & Director · born 1972
- Ms. Qing ChangDeputy GM, Deputy Secretary of the Party Branch & Director · born 1979